Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis

<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>. </b><a href="https://link.springer.com/article/10.1007/s40744-016-0049-8">https://link.springer.com/article/10.1007/s40744-016-0049-8</a></p><p></p> <p><br></p> <p><b>Provide enhanced content for this article</b></p> <p><br></p> <p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p> <p><br></p> <p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p> <p><br></p> <p>Other enhanced features include, but are not limited to:</p> <p><br></p> <p>• Slide decks</p> <p>• Videos and animations</p> <p>• Audio abstracts</p> <p>• Audio slides</p

Kaplan-Meier curves for the primary end point (panel A), as well as for all-cause (B) and CV (C) mortality according to tertile sFRP3 concentration.

<p>T1, lowest tertile serum sFRP3; T3, highest tertile serum sFRP3. Patients with T2 sFRP3 showed a markedly better outcome than patients in T1 and T2; <i>p</i><0.001 for the primary end point and all-cause mortality, <i>p</i><0.002 for CV mortality.</p

Clinical and biochemical baseline characteristics stratified by tertile values of sFRP3.

<p>NT-proBNP and CRP are displayed as median value (interquartile range). Other variables are shown as number (percentage of total) or as mean (standard deviation) where appropriate. <i>P</i>-value Trend, <i>p</i>-value for trend across all tertiles; <i>P</i>-value 2^nd, <i>p</i>-value for 2^nd tertile compared to 1^st and 3^rd tertile combined.NYHA, New York Heart Association; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; LDL, low-density lipoprotein; HDL, high-density lipoprotein; ApoB, apolipoprotein B; ApoA-1, apolipoprotein A-1; eGFR, estimated glomerular filtration rate; MDRD, modification of diet in renal disease; CRP, C-reactive protein; NT-proBNP, amino-terminal pro-brain natriuretic peptide; sFRP3, secreted frizzled related protein 3; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker.</p><p>Clinical and biochemical baseline characteristics stratified by tertile values of sFRP3.</p

Multivariable analysis of intermediate levels of sFRP3 as a predictor of outcome.

<p>sFRP3, 2^nd tertile <i>vs</i>. 1^st and 3^rd tertile, as predictor of outcome. All Hazard Ratios (HR) are given as HR (95% confidence interval). C index, Δ; difference in C index between fully adjusted model with and without inclusion of sFRP3, corresponding (<i>p</i>-value). Net Reclassification Improvement (NRI); calculated from C-indexes for fully adjusted models with and without inclusion of sFRP3, corresponding (<i>p</i>-value). Unadjusted (n = 1444). The models are adjusted as follows: Step 1 (n = 1441): Ejection fraction, New York Heart Association functional class, age, body mass index, diabetes mellitus, sex, intermittent claudication and heart rate. Step 2 (n = 1428): All variables from Step 1 as well as ApoB/Apo A-1 ratio and estimated glomerular filtration rate. Step 3 (1194): all variables from Step 2 as well as C-reactive protein and amino-terminal pro B-type natriuretic peptide. CV, cardiovascular; WHF, worsening heart failure.</p><p>Multivariable analysis of intermediate levels of sFRP3 as a predictor of outcome.</p

Discriminatory properties of sFRP3.

<p>Area under curve (AUC) and 95% Confidence interval (CI) of sFRP3 as a categorical (1. and 3. tertile <i>vs</i>. 2. tertile) variable, corresponding <i>p</i>-value.</p

Results of blood tests.

<p>* p < 0.05 for difference between baseline and follow-up. CI: confidence interval; LDL: low density lipoprotein; HDL: high density lipoprotein; NT-proBNP: N-terminal pro-B-type natriuretic peptide; sTNF-R1: soluble tumour necrosis factor receptor 1; MCP-1: monocyte chemotactic protein-1; gp130: Soluble glycoprotein 130; MMP-9: matrix metalloproteinase-9; PINP: procollagen type I N-terminal pro-peptide; PIIINP: procollagen type III N-terminal pro-peptide.</p